{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:34:36Z","timestamp":1791326076606,"version":"4.3.1"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.coviro.2016.06.003","type":"journal-article","created":{"date-parts":[[2016,7,20]],"date-time":"2016-07-20T18:45:18Z","timestamp":1469040318000},"page":"135-143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"special_numbering":"C","title":["HBV cure: why, how, when?"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4978-0875","authenticated-orcid":false,"given":"Massimo","family":"Levrero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Testoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Zoulim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2016.06.003_bib0385","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.coviro.2016.06.004","article-title":"Current treatments for chronic hepatitis B virus infections","volume":"18","author":"Zoulim","year":"2016","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.coviro.2016.06.003_bib0390","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1136\/gutjnl-2014-308943","article-title":"Towards an HBV cure: state-of-the-art and unresolved questions \u2013 report of the ANRS workshop on HBV cure","volume":"64","author":"Zeisel","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.coviro.2016.06.003_bib0395","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.jhep.2016.02.021","article-title":"Mechanisms of HBV-induced hepatocellular carcinoma","volume":"64","author":"Levrero","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2016.06.003_bib0400","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","article-title":"Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity","volume":"30","author":"Ott","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2016.06.003_bib0405","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.gastro.2014.04.030","article-title":"Strategies to inhibit entry of HBV and HDV into hepatocytes","volume":"147","author":"Urban","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2016.06.003_bib0410","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/hep.21896","article-title":"virus infection initiate with a large surface protein-dependent binding to heparan sulfate proteoglycans","volume":"46","author":"Schulze","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2016.06.003_sbref0415","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/hep.28013","article-title":"A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses","volume":"63","author":"Verrier","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2016.06.003_sbref0420","doi-asserted-by":"crossref","first-page":"e00049","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"Elife"},{"key":"10.1016\/j.coviro.2016.06.003_bib0425","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1053\/j.gastro.2013.12.024","article-title":"Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes","volume":"146","author":"Ni","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2016.06.003_bib0430","doi-asserted-by":"crossref","first-page":"9443","DOI":"10.1128\/JVI.00873-12","article-title":"Entry of hepatitis B virus into immortalized human primary hepatocytes by clathrin-dependent endocytosis","volume":"86","author":"Huang","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.06.003_bib0435","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1128\/JVI.01207-09","article-title":"virus requires intact caveolin-1 function for productive infection in HepaRG cells","volume":"84","author":"Macovei","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.06.003_bib0440","doi-asserted-by":"crossref","first-page":"e1000741","DOI":"10.1371\/journal.ppat.1000741","article-title":"Nucleoporin 153 arrests the nuclear import of hepatitis B virus capsids in the nuclear basket","volume":"6","author":"Schmitz","year":"2010","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2016.06.003_bib0445","doi-asserted-by":"crossref","first-page":"E4244","DOI":"10.1073\/pnas.1409986111","article-title":"Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses","volume":"111","author":"Koniger","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coviro.2016.06.003_bib0450","doi-asserted-by":"crossref","first-page":"e0128401","DOI":"10.1371\/journal.pone.0128401","article-title":"Does tyrosyl DNA phosphodiesterase-2 play a role in hepatitis B virus genome repair","volume":"10","author":"Cui","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1016\/j.coviro.2016.06.003_sbref0455","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1053\/j.gastro.2006.01.001","article-title":"Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones","volume":"130","author":"Pollicino","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2016.06.003_bib0460","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1006\/jmbi.2000.4481","article-title":"Structural organization of the hepatitis B virus minichromosome","volume":"307","author":"Bock","year":"2001","journal-title":"J Mol Biol"},{"key":"10.1016\/j.coviro.2016.06.003_bib0465","doi-asserted-by":"crossref","first-page":"19975","DOI":"10.1073\/pnas.0908365106","article-title":"Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function","volume":"106","author":"Belloni","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coviro.2016.06.003_sbref0470","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.jhep.2011.02.015","article-title":"Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection","volume":"55","author":"Lucifora","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2016.06.003_bib0475","doi-asserted-by":"crossref","first-page":"10205","DOI":"10.1073\/pnas.0704000104","article-title":"Involvement of host cellular multivesicular body functions in hepatitis B virus budding","volume":"104","author":"Watanabe","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coviro.2016.06.003_bib0480","doi-asserted-by":"crossref","first-page":"11916","DOI":"10.1128\/JVI.05373-11","article-title":"Roles of the envelope proteins in the amplification of covalently closed circular DNA and completion of synthesis of the plus-strand DNA in hepatitis B virus","volume":"85","author":"Lentz","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.06.003_bib0485","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1053\/j.gastro.2004.03.018","article-title":"Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy","volume":"126","author":"Werle-Lapostolle","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2016.06.003_bib0490","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1126\/science.284.5415.825","article-title":"Viral clearance without destruction of infected cells during acute HBV infection","volume":"284","author":"Guidotti","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.coviro.2016.06.003_bib0495","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/hep.27323","article-title":"Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections","volume":"61","author":"Rehermann","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2016.06.003_bib0500","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/liv.12749","article-title":"HBV and the immune response","volume":"35","author":"Ferrari","year":"2015","journal-title":"Liver Int."},{"key":"10.1016\/j.coviro.2016.06.003_bib0505","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1146\/annurev.pathol.1.110304.100230","article-title":"Immunobiology and pathogenesis of viral hepatitis","volume":"1","author":"Guidotti","year":"2006","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.coviro.2016.06.003_bib0510","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1073\/pnas.0401771101","article-title":"Genomic analysis of the host response to hepatitis B virus infection","volume":"101","author":"Wieland","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coviro.2016.06.003_bib0515","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/hep.23230","article-title":"Control of hepatitis B virus replication by innate response of HepaRG cells","volume":"51","author":"Lucifora","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2016.06.003_bib0520","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.antiviral.2015.08.008","article-title":"Immune-modulators to combat hepatitis B virus infection: From IFN-\u03b1 to novel investigational immunotherapeutic strategies","volume":"122","author":"Isorce","year":"2015","journal-title":"Antivir Res"},{"key":"10.1016\/j.coviro.2016.06.003_bib0525","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.virol.2015.02.031","article-title":"Molecular biology of hepatitis B virus infection","volume":"479\u2013480","author":"Seeger","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2016.06.003_bib0530","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/jvh.12380","article-title":"Clonal expansion of hepatocytes with a selective advantage occurs during all stages of chronic hepatitis B virus infection","volume":"22","author":"Tu","year":"2015","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.coviro.2016.06.003_bib0535","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"Easl clinical practice guidelines: management of chronic hepatitis B virus infection","volume":"57","author":"EASL","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2016.06.003_bib0540","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jhep.2012.11.007","article-title":"Dissecting the divergent effects of interferon-alpha on immune cells: time to rethink combination therapy in chronic hepatitis B?","volume":"58","author":"Thimme","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2016.06.003_bib0545","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jhep.2012.09.029","article-title":"Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B","volume":"58","author":"Micco","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2016.06.003_sbref0550","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1172\/JCI58847","article-title":"IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome","volume":"122","author":"Belloni","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coviro.2016.06.003_bib0555","doi-asserted-by":"crossref","first-page":"e1003613","DOI":"10.1371\/journal.ppat.1003613","article-title":"Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes","volume":"9","author":"Liu","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2016.06.003_bib0560","doi-asserted-by":"crossref","first-page":"S214","DOI":"10.1016\/S0168-8278(15)30134-3","article-title":"High antiviral activity of the HBV core inhibitor NVR 3-778 in the humanized uPA\/SCID mouse model","volume":"62","author":"Klumpp","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2016.06.003_sbref0565","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.coviro.2016.06.003_bib0570","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1053\/j.gastro.2015.09.026","article-title":"Interferon-\u03b3 and tumor necrosis factor-\u03b1 produced by T cells reduce the HBV persistence form, cccDNA, without cytolysis","volume":"150","author":"Xia","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2016.06.003_bib0575","article-title":"Evidence for ongoing low level viremia in patients with CHB receiving long term NUC therapy","author":"Marcellin","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2016.06.003_bib0580","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/hep.24758","article-title":"Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation","volume":"55","author":"L\u00fctgehetmann","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2016.06.003_bib0585","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.antiviral.2015.06.020","article-title":"Core prote pleiotropic keystone in the A HBV lifecycle","volume":"121","author":"Zlotnick","year":"2015","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2016.06.003_bib0590","doi-asserted-by":"crossref","first-page":"S513","DOI":"10.1016\/S0168-8278(15)30737-6","article-title":"Capsid drugs HAP12 and AT130 target HBV core protein nuclear functions","volume":"62","author":"Belloni","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2016.06.003_bib0595","first-page":"276A","article-title":"The nuclear function of Hepatitis B capsid (HBc) protein is to inhibit IFN response very early after infection of hepatocytes","volume":"58","author":"Gruffaz","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2016.06.003_bib0600","first-page":"1385A","article-title":"Phase 1b efficacy and safety of NVR 3-778, a first-in- class HBV core inhibitor, in HBeAg-positive patients with chronic HBV infection","volume":"62","author":"Yuen","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2016.06.003_bib0605","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/mt.2013.31","article-title":"Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection","volume":"21","author":"Wooddell","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.coviro.2016.06.003_bib0610","first-page":"LB9","article-title":"ARC-520 produces deep and durable knockdown of viral antigens and DNA in a phase II study in patients with chronic hepatitis B","volume":"62","author":"Yuen","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2016.06.003_bib0615","first-page":"32A","article-title":"Reductions in cccDNA under NUC and ARC-520 therapy in chimpanzees with chronic hepatitis B virus infection implicate integrated DNA in maintaining circulating HBsAg","volume":"62","author":"Wooddell","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2016.06.003_bib0620","series-title":"10th annual meeting of the oligonucleotide therapeutics society","article-title":"Update on the preclinical development of an LNP-based HBV therapeutic","year":"2014"},{"key":"10.1016\/j.coviro.2016.06.003_bib0625","first-page":"222A","article-title":"Update on the safety and efficacy of REP 2139 monotherapy and subsequent combination therapy with pegylated interferon alpha-2a in chronic HBV\/HDV co-infection in Caucasian patients","volume":"62","author":"Bazinet","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2016.06.003_bib0630","series-title":"Combination therapy with the nucleic acid polymer REP 2139-Ca and nucleos(t)ide analogues improves antiviral responses against hepatitis B in vivo. HepDart 2015","author":"Quinet","year":"2015"},{"key":"10.1016\/j.coviro.2016.06.003_bib0635","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1002\/hep.23936","article-title":"The immunoregulatory role of CD244 in chronic hepatitis B infection and its inhibitory potential on virus-specific CD8+ T-cell function","volume":"52","author":"Raziorrouh","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2016.06.003_bib0640","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.gastro.2009.09.052","article-title":"Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B","volume":"138","author":"Fisicaro","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2016.06.003_bib0645","doi-asserted-by":"crossref","first-page":"e1001227","DOI":"10.1371\/journal.ppat.1001227","article-title":"Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection","volume":"6","author":"Peppa","year":"2010","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2016.06.003_bib0650","doi-asserted-by":"crossref","first-page":"TPS3111","DOI":"10.1200\/jco.2013.31.15_suppl.tps3111","article-title":"Phase I dose escalation study of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis","volume":"31","author":"Sangro","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coviro.2016.06.003_bib0655","doi-asserted-by":"crossref","first-page":"S188","DOI":"10.1016\/S0168-8278(15)30005-2","article-title":"Engineered HBV-specific T cells: disentangling antiviral from killing capacity","volume":"62","author":"Koh","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2016.06.003_bib0660","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1053\/j.gastro.2013.04.047","article-title":"T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice","volume":"145","author":"Krebs","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2016.06.003_sbref0665","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2014.10.001","article-title":"Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient","volume":"62","author":"Qasim","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2016.06.003_bib0670","first-page":"302","article-title":"Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B","volume":"64","author":"Lok","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2016.06.003_bib0675","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1136\/gutjnl-2014-308041","article-title":"TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice","volume":"64","author":"Martin","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.coviro.2016.06.003_bib0680","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1053\/j.gastro.2013.02.003","article-title":"GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees","volume":"144","author":"Lanford","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2016.06.003_sbref0685","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jhep.2015.02.037","article-title":"The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection","volume":"63","author":"Gane","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2016.06.003_bib0690","first-page":"1187A","article-title":"Functional activation of NK and CD8+ T cells in vitro by the toll-like receptor 7 agonist GS-9620","volume":"62","author":"Steuer","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2016.06.003_sbref0695","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.immuni.2014.12.016","article-title":"The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus","volume":"42","author":"Sato","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.coviro.2016.06.003_bib0700","doi-asserted-by":"crossref","first-page":"557A","DOI":"10.1016\/S0168-8278(15)30841-2","article-title":"Antiviral efficacy and induction of host immune responses with SB 9200, an oral prodrug of the dinucleotide SB 9000, in the woodchuck model of chronic Hepatitis B Virus (HBV) infection","volume":"62","author":"Korolowicz","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2016.06.003_bib0705","doi-asserted-by":"crossref","first-page":"5797","DOI":"10.1073\/pnas.1502390112","article-title":"Cellular inhibitor of apoptosis proteins prevent clearance of hepatitis B virus","volume":"112","author":"Ebert","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2016.06.003_sbref0710","doi-asserted-by":"crossref","first-page":"5803","DOI":"10.1073\/pnas.1502400112","article-title":"Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis","volume":"112","author":"Ebert","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2016.06.003_bib0715","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1128\/AAC.00473-12","article-title":"Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation","volume":"56","author":"Cai","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2016.06.003_bib0720","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1038\/mt.2013.170","article-title":"Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases","volume":"21","author":"Bloom","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.coviro.2016.06.003_bib0725","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.antiviral.2015.10.004","article-title":"Targeting hepatitis B virus cccDNA using CRISPR\/Cas9","volume":"123","author":"Kennedy","year":"2015","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2016.06.003_bib0730","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.virol.2014.12.001","article-title":"Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR\/Cas RNA-guided DNA endonuclease","volume":"476","author":"Kennedy","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2016.06.003_bib0735","doi-asserted-by":"crossref","first-page":"10833","DOI":"10.1038\/srep10833","article-title":"CRISPR\/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus","volume":"5","author":"Ramanan","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.coviro.2016.06.003_bib0740","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1038\/mtna.2014.68","article-title":"Targeting Hepatitis B Virus with CRISPR\/Cas9","volume":"3","author":"Seeger","year":"2014","journal-title":"Mol Ther Nucleic acids"},{"key":"10.1016\/j.coviro.2016.06.003_bib0745","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1038\/mtna.2014.38","article-title":"The CRISPR\/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo","volume":"3","author":"Lin","year":"2014","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.coviro.2016.06.003_bib0750","first-page":"309A","article-title":"Silencing HBV transcription by targeting cccDNA-bound chromatin modifiers","volume":"60","author":"Palumbo","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2016.06.003_sbref0755","doi-asserted-by":"crossref","first-page":"E5715","DOI":"10.1073\/pnas.1518090112","article-title":"Mapping of histone modifications in episomal HBV cccDNA uncovers an unusual chromatin organization amenable to epigenetic manipulation","volume":"112","author":"Tropberger","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2016.06.003_sbref0760","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nature17170","article-title":"Hepatitis B virus X protein identifies the Smc5\/6 complex as a host restriction factor","volume":"531","author":"Decorsi\u00e8re","year":"2016","journal-title":"Nature"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625716300657?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625716300657?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T13:57:10Z","timestamp":1656856630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625716300657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":76,"alternative-id":["S1879625716300657"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2016.06.003","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HBV cure: why, how, when?","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2016.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}